Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Paclitaxel vs Bevacizumab + Cyclophosphamide + Capecitabine in 1L HER2-Negative Metastatic Breast Cancer
NCT01131195Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jul 2010
- Primary completion
- Dec 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in breast cancer, sponsored by Swiss Group for Clinical Cancer Research. Started Jul 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01131195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01131195.